American Pharmacy News
  • People
  • Innovation
  • Regulatory
  • Industry
  • Federal Issues
  • State Issues
  • Directory
  • People
  • Innovation
  • Regulatory
  • Industry
  • Federal Issues
  • State Issues
  • Directory
  • Home
  • »
  • Stories
  • »
  • 2017

AbbVie's HCV injection drug Maviret receives positive opinion

American Pharmacy News Reports | Jul 2, 2017
 EMA is giving AbbVie an accelerated assessment to the marketing authorization application for Maviret.

AbbVie's chronic hepatitis C virus infection drug, Maviret, was granted a positive opinion by the European Committee for Medicinal Products for Human Use of the European Medicines Agency. Read More »

Amgen's Mimpara given position opinion in Europe

American Pharmacy News Reports | Jul 2, 2017
The European Commission will now review the CHMP positive opinion.

Amgen recently announced that its Mimpara drug has been given a positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency. Read More »

Advair Diskus application accepted by FDA

American Pharmacy News Reports | Jul 3, 2017
Advair Diskus will treat patients 4 and older who suffer from asthma.

Sandoz's Abbreviated New Drug Application for fluticasone propionate/salmeterol combination product, a substitutable generic version of Advair Diskus, was accepted by the U.S. Food and Drug Administration. Read More »

Ipsen's Dysport approved for expanded use by FDA

American Pharmacy News Reports | Jul 3, 2017
Dysport is currently the only botulinum toxin approved by the FDA for the treatment of spasticity in adults.

Ipsen Biopharmaceuticals Inc., an affiliate of Ipsen SA, has had its Dysport injection for treating spasticity in adults approved for expanded use by the U.S. Food and Drug Administration. Read More »

CSL Behring's drug for reducing HAE attacks approved

American Pharmacy News Reports | Jul 3, 2017
A Phase III study confirmed the safety and efficacy of Haegarda.

CSL Behring's Haegarda drug, the only subcutaneous therapy for preventing hereditary angioedema attacks in both adolescents and adults, was approved by the U.S. Food and Drug Administration. Read More »

Lexicon releases results from diabetes drug studies

American Pharmacy News Reports | Jul 6, 2017
The two studies covered 24 weeks of data analyzing the drug in patients with Type 1 diabetes.

Lexicon Pharmaceuticals Inc. recently presented its two sotagliflozin studies, inTandem1 and inTandem2, at the 77th American Diabetes Association Scientific Sessions in San Diego, California. Read More »

FDA OKs Darzalex immunotherapy for multiple myleoma patients

American Pharmacy News Reports | Jul 6, 2017
Janssen Biotech's Darzalex immunotherapy was approved by the U.S. Food and Drug Administration.

Janssen Biotech's Darzalex immunotherapy was approved by the U.S. Food and Drug Administration for treating patients with multiple myeloma in combination with pomalidomide and dexamethasone. Read More »

Pfizer study shows Xeljanz on par with Humira for treating rheumatoid arthritis

American Pharmacy News Reports | Jul 6, 2017
Xeljanz is a twice-daily monotherapy to be used in combination with methotrexate.

Pfizer Inc. recently published noninferiority results from its study of Xeljanz, a twice-daily monotherapy to be used in combination with methotrexate in treating patients with moderate to severe rheumatoid arthritis. Read More »

DelMar presents info on new cancer-fighting product at pediatric neuro-oncology conference

American Pharmacy News Reports | Jul 6, 2017
DelMar Pharmaceuticals recently presented a poster on dianhydrogalactitol.

DelMar Pharmaceuticals recently presented a poster on dianhydrogalactitol at the Society for Neuro-Oncology's 4th Pediatric Neuro-Oncology Basic and Translational Research Conference, which took place at the Wyndham New Yorker Hotel in New York City in June. Read More »

FDA seeks additional details on Egalet’s Oxaydo application

American Pharmacy News Reports | Jul 6, 2017
Oxaydo works as an immediate-release medication to manage acute and chronic moderate to severe pain.

Egalet Corp. of Pennsylvania recently obtained a complete response letter from the U.S. Food and Drug Administration about its Oxaydo tablets in 10 mg and 15 mg dosage strengths. Read More »

GSK reveals 10-year study success with lupus drug

American Pharmacy News Reports | Jul 6, 2017
The percentage of lupus patients responsive to treatment with belimumab was found to increase over time.

A decade-long study of GSK’s Benlysta — the longest to date — recently culminated with indications of the drug’s safety and efficacy against active systemic lupus erythematosus, when administered with standard care. Read More »

DelMar leaders join brain tumor society's research roundtable

American Pharmacy News Reports | Jul 6, 2017
Jeffrey Bacha and Dennis Brown participated alongside peers in the neuro-oncology field.

Two DelMar Pharmaceuticals Inc. executives recently accepted requests to join the National Brain Tumor Society's Research Roundtable, attending its premiere meeting in Washington, D.C. to consider ways research can improve clinical trials for regulatory approval. Read More »

FDA grants Biohaven's BHV-5000 orphan drug status

American Pharmacy News Reports | Jul 6, 2017
BHV-5000 was licensed to Biohaven from AstraZeneca in late 2016.

New Haven, Connecticut-based Biohaven Pharmaceutical Holding Company Ltd.’s BHV-5000 compound developed to treat Rett syndrome recently attained orphan drug designation from the U.S. Food and Drug Administration (FDA), its fourth product to achieve the status. Read More »

Alexion attains support for Strensiq to address HPP

American Pharmacy News Reports | Jul 6, 2017
Strensiq has already won approval in the European Union for individuals with pediatric-onset HPP as an enzyme replacement therapy.

Pediatric-onset hypophosphatasia, an extremely rare metabolic disease affecting bone structure and strength, came into sharper focus recently when Alexion Pharmaceuticals won funding for its Strensiq medication from two sources via a managed access agreement. Read More »

McKesson acquires intraFUSION

American Pharmacy News Reports | Jul 7, 2017
The acquisition closely relates to McKesson's overall goal of increasing the quality of specialty care.

McKesson Specialty Health has acquired intraFUSION. Read More »

SteadyMed submits new drug application for Trevyent

American Pharmacy News Reports | Jul 7, 2017
PatchPump is a disposable drug administration tool that is filled onsite with the manufacturer.

Cardiome Pharma Corp. partner SteadyMed Ltd. has submitted a New Drug Application for Trevyent with the U.S. Food and Drug Administration. Read More »

Novo Nordisk recalls cartridge holders

American Pharmacy News Reports | Jul 7, 2017
The batches in question were dispensed between Aug. 1, 2016 and June 22, 2017.

Novo Nordisk is recalling insulin cartridge holders of the NovoPen Echo model, warning that they may crack if they are in the presence of chemicals, such as those found in cleaners. Read More »

Pfizer and Merck's Type 2 diabetes drug passes primary endpoints

American Pharmacy News Reports | Jul 7, 2017
In both studies, the drug met its primary endpoint.

Pfizer Inc. and Merck released positive data from two Phase 3 studies of ertugliflozin, an investigational oral GGLT-2 inhibitor that seeks to treat Type 2 diabetes patients by improving glycemic control. Read More »

Agile Therapeutics resubmits application for Twirla contraceptive patch

American Pharmacy News Reports | Jul 8, 2017
Twirla is an investigational low-dose transdermal patch.

Progressive women's health care company Agile Therapeutics Inc. of Princeton, New Jersey has resubmitted its Twirla hormonal contraceptive patch to the U.S. Food and Drug Administration for a New Drug Application. Read More »

Benznidazole for Chagas disease gains FDA clearance

American Pharmacy News Reports | Jul 8, 2017
Chagas disease is caused by the Trypanosoma cruzi parasite and is spread mainly by insects.

KaloBios Pharmaceuticals Inc. of California, specializing in rare and neglected diseases, recently obtained FDA clearance for its oral anti-parasitic medication benznidazole designed to combat Chagas disease, a tropical malady transmitted to humans by insects. Read More »

  • «
  • 1
  • 2
  • ...
  • 26
  • 27
  • 28 (current)
  • 29
  • 30
  • ...
  • 36
  • 37
  • »
Trending

 B. Douglas Hoey CEO

NCPA urges government action on pharmacy benefit managers' practices

John Kirtley Executive Director at Arkansas State Board of Pharmacy

Women's health block party to launch National Women's Health Month at Arkansas State Capitol

John Kirtley Executive Director at Arkansas State Board of Pharmacy

Arkansas Health Department extends hours for REAL ID birth certificate requests

 B. Douglas Hoey CEO

NCPA releases new "Show Me" episodes about maternal vaccination programs

Copyright © 2025 American Pharmacy News. All Rights Reserved.

  • About
  • Contact
  • Privacy Policy
  • Terms of Service

Alerts Sign-up